Dutch Stem Cell Biotech Neuroplast Secures € 10 Million (Us$ 11.5 Million) In Series B Funding To Further Advance Its Transformative Stem Cell Therapy For Traumatic Spinal Cord Injury

Nov 17, 2021•over 3 years ago

Amount Raised

€10 Million

Round Type

series b

Geleen

Description

Dutch clinical phase biotech Neuroplast raised a total of € 10 million (US$ 11.5 million) in funding from investors Lumana Invest, Brightlands Venture Partners, LIOF, and from the Innovation Credit from the Netherlands Enterprise Agency, to further advance the clinical development of a transformative treatment for Traumatic Spinal Cord Injury (TSCI). Neuroplast will use this Series B funding to obtain conditional EMA market approval for its Neuro-Cells® stem cell therapy.

Company Information

Company

Neuroplast

Location

Geleen, Limburg, Netherlands

About

Neuroplast is a Dutch stem cell technology company focusing on fast-track development programs using autologous cell products for treatment of primarily inflammation-driven neurological disorders, with the aim of giving back perspective to people who suffer from those conditions. The company was founded in August 2014 by physician Johannes de Munter and neurologist Erik Wolters. Current investors are Lumana Invest, Brightlands Venture Partners, LIOF and the Netherlands Enterprise Agency. Neuroplast is located in Brightlands Chemelot Campus in The Netherlands.

Funding Insights

Based on industry data

Tech investment trends

83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech

Dutch Stem Cell Biotech Neuroplast Secures € 10 Million (Us$ 11.5 Million) In Series B Funding To Further Advance Its Transformative Stem Cell Therapy For Traumatic Spinal Cord Injury

Description

.css-1v6jzuu{--tw-text-opacity:1;color:rgba(75, 85, 99, var(--tw-text-opacity));}Company Information

Funding Insights

Company Information